Home › Portfolio Model Subscription › Novo Nordisk (NVO-$84.66, NYSE). Approval for Wegovy Quietly Granted During the Covid-19 Obsessed Media Cycle. Potential for a Mega-blockbuster Goes Largely Unnoticed.

Novo Nordisk (NVO-$84.66, NYSE). Approval for Wegovy Quietly Granted During the Covid-19 Obsessed Media Cycle. Potential for a Mega-blockbuster Goes Largely Unnoticed.

Posted on June 10, 2021 by Randolph McDuff — No Comments ↓

https://finance.yahoo.com/news/wegovy-semaglutide-2-4-mg-181000882.html

Posted in Portfolio Model Subscription

Leave a Reply

Recent Comments
    Archives